Cinical Effect of Restasis® Eye Drops in Mild Dry Eye Syndrome

Purpose: To evaluate changes in tear secretion and symptoms in patients with mild dry eye syndrome after using Restasis. Methods: From patients diagnosed with mild dry eye syndrome, Restasis was administered to 46 eyes of 23 patients. The clinical parameters and symptoms were checked over a period of six months. The clinical parameters evaluated were the symptoms of dry eye syndrome using an OSDI scoring scale, the Schirmer test, and tear break-up time. Results: Eight male patients and 15 female patients were included in the study. The mean age was 50.5 years. Before treatment, the values for the OSDI score, BUT, and Schirmer test were 32.3, 5.3 mm, and 8.1 seconds, respectively. After treatment, the OSDI score, BUT, and Schirmer test were 22.9, 8.1 mm, and 12.1 seconds at six months, respectively. The subjective parameter (OSDI score) improved two months after treatment (p=0.003), and the objective parameters (BUT, Schirmer test) improved three months after treatment (p=0.03, p=0.04, respectively). Conclusions: In the present study, Restasis increased tear secretion and improved clinical symptoms of patients with mild dry eye.

[1]  E. Donnenfeld,et al.  Evaluation of topical cyclosporine for the treatment of dry eye disease. , 2008, Archives of ophthalmology.

[2]  Tae-im Kim,et al.  The Short-Term Effect of Topical Cyclosporine A 0.05% in Various Ocular Surface Disorder , 2008 .

[3]  R. D. Stulting,et al.  Agreement of Physician Treatment Practices With the International Task Force Guidelines for Diagnosis and Treatment of Dry Eye Disease , 2007, Cornea.

[4]  Terry Kim,et al.  Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren's syndrome. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[5]  H. Perry,et al.  Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. , 2007, Ophthalmology.

[6]  S. Pflugfelder,et al.  Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. , 2005, Ophthalmology.

[7]  E. Donnenfeld,et al.  Topical 0.05% cyclosporin in the treatment of dry eye , 2004, Expert opinion on pharmacotherapy.

[8]  P. O’Brien,et al.  Dry eye: Diagnosis and current treatment strategies , 2004, Current allergy and asthma reports.

[9]  K. Tsubota,et al.  New insights into the diagnosis and treatment of dry eye. , 2004, The ocular surface.

[10]  S. Pflugfelder,et al.  Inflammation in dry eye. , 2004, The ocular surface.

[11]  C. Baudouin,et al.  Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. , 2001, Investigative ophthalmology & visual science.

[12]  I. Gipson,et al.  Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. , 2000, Archives of ophthalmology.

[13]  B. Reis,et al.  Efficacy and safety of cyclosporin a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial☆ , 2000 .

[14]  B. Reis,et al.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease1 , 2000 .

[15]  P. Mullaney,et al.  Effect of Topical Cyclosporin A on Conjunctival T Cells in Patients with Secondary Sjögren’s Syndrome , 1993, Cornea.

[16]  M. O’connell,et al.  Pilot Trial of Cyclosporine 1% Ophthalmic Ointment in the Treatment of Keratoconjunctivitis Sicca , 1993, Cornea.